

Laszlo Perlaky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10109024/publications.pdf>

Version: 2024-02-01

16
papers

354
citations

1163117

8
h-index

1199594

12
g-index

18
all docs

18
docs citations

18
times ranked

792
citing authors

#	ARTICLE	IF	CITATIONS
1	Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma. <i>Translational Oncology</i> , 2022, 18, 101368.	3.7	2
2	Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion. <i>Advanced Science</i> , 2021, 8, e2101923.	11.2	11
3	EPEN-46. DNA METHYLATION LANDSCAPE OF RECURRENT PEDIATRIC EPENDYMOMA IDENTIFIES KEY DRIVER EVENTS. <i>Neuro-Oncology</i> , 2020, 22, iii317-iii317.	1.2	0
4	EXTH-45. THERAPEUTIC EFFICACY OF MUTANT ISOCITRATE DEHYDROGENASE 1 (IDH1) INHIBITOR SYC-435 WITH STANDARD THERAPY IN PATIENT-DERIVED IDH1 MUTANT GLIOMA XENOGRAFT MOUSE MODELS. <i>Neuro-Oncology</i> , 2019, 21, vi91-vi92.	1.2	0
5	Establishment and genomic characterization of primary salivary duct carcinoma cell line. <i>Oral Oncology</i> , 2017, 69, 108-114.	1.5	5
6	A novel prognostic model for osteosarcoma using circulating <sc>CXCL</sc>10 and <sc>FLT</sc>3<sc>LG</sc>. <i>Cancer</i> , 2017, 123, 144-154.	4.1	26
7	EXTH-07. MUTANT ISOCITRATE DEHYDROGENASE 1 (IDH1) INHIBITOR SYC-435 SYNERGISTICALLY PROLONGS ANIMAL SURVIVAL WITH STANDARD THERAPIES IN PATIENT-DERIVED IDH1 MUTANT GLIOMA XENOGRAFT MOUSE MODELS. <i>Neuro-Oncology</i> , 2017, 19, vi74-vi74.	1.2	0
8	Xenotransplantation of pediatric low grade gliomas confirms the enrichment of <i>BRAF</i> V600E mutation and preservation of <i>CDKN2A</i> deletion in a novel orthotopic xenograft mouse model of progressive pleomorphic xanthoastrocytoma. <i>Oncotarget</i> , 2017, 8, 87455-87471.	1.8	21
9	Biocompatibility of reduced graphene oxide nanoscaffolds following acute spinal cord injury in rats. <i>ACS Applied Materials</i> , 2016, 7, 75.		34
10	Stromal <sc>CYR</sc>61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 704-718.	2.5	27
11	A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children. <i>Neuro-Oncology</i> , 2014, 16, 787-799.	1.2	15
12	Development and characterization of salivary adenoid cystic carcinoma cell line. <i>Oral Oncology</i> , 2014, 50, 991-999.	1.5	23
13	Stromal CYR61 Confers Resistance to Mitoxantrone Via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2228-2228.	1.4	0
14	Direct Orthotopic Transplantation of Fresh Surgical Specimen Preserves CD133+ Tumor Cells in Clinically Relevant Mouse Models of Medulloblastoma and Glioma. <i>Stem Cells</i> , 2008, 26, 1414-1424.	3.2	127
15	The 58-kDa microspherule protein (MSP58), a nucleolar protein, interacts with nucleolar protein p120. <i>FEBS Journal</i> , 1998, 253, 734-742.	0.2	55
16	Cloning and characterization of a new silver-stainable protein SSP29, a member of the LRR family. <i>IUBMB Life</i> , 1997, 42, 927-935.	3.4	7